Glycotope Biotechnology and Cantargia Sign Production Agreement for Lead Product Candidate CAN04
Cantargia and Glycotope Biotechnology have announced an agreement on the production of Cantargia's proprietary monoclonal antibody CAN04. The product candidate CAN04 is directed against the target molecule IL1RAP, expressed on cancer stem cells, as well on mature cancer cells. Through the agreement, Glycotope Biotechnology will be Cantargia's production partner to obtain material for the clinical studies of CAN04 in cancer patients.
Glycotope Biotechnology will be responsible for the development and the GMP (Good Manufacturing Practices) production of CAN04. Glycotope Biotechnology will manufacture the material to be used in both future toxicology studies and clinical trials.
"The collaboration with Glycotope Biotechnology will be a cornerstone in the development of CAN04. We look forward to work with Glycotope Biotechnology", says Göran Forsberg, CEO of Cantargia.
"To bring Cantargia's lead drug candidate into clinical trials will be a great opportunity for Glycotope Biotechnology as Contract Manufacturer for innovative biopharmaceuticals", says Franzpeter Bracht, COO of Glycotope Biotechnology.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
.png)
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
.png)
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
.png)
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
.png)
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
.png)
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance